Identification of pyroptosis-associated miRNAs in the immunoscape and prognosis of hepatocellular carcinoma Authors: Yuting Zheng, Xing Huang Published: 2024 ABSTRACT AbstractBackgroundHepatocellular carcinoma is one of the most prevalent types of liver malignancy and poses a severe threat to global health. Despite recent improvements in therapeutic approaches, treatment options for patients with advanced or recurrent HCC are still limited.Materials and methodsOur study analyzed miRNA differential expression using data from hepatocellular carcinoma patients in the Cancer Genome Atlas. Pyroptosis-related genes were identified from gene cards. Differential expression of miRNAs was analyzed using DESeq2 and visualized using ggplot2 and pheatmap. A prognostic risk model for pyroptosis-associated miRNAs was constructed using LASSO regression and validated by principal component analysis, Kaplan-Meier survival and ROC curve analysis. We also performed gene and pathway enrichment analysis. Immune cell infiltration and function in HCC were assessed using single-sample genomic enrichment analysis, and correlations with immune cells and function were explored. Also, CCK-8 assay as well as migration and invasion assays were performed after knockdown of miR-6844.ResultsWe have established and validated a prognostic risk model based on ten DEmiRNAs, which is important for the survival of HCC patients. Significant changes in immune cell infiltration and immune function were also found in high-risk patients. It also demonstrated that knockdown of miR-6844 inhibited HCC cell proliferation, migration and invasion, highlighting its role in HCC progression.ConclusionOur study reveals the implications of pyroptosis-associated differential miRNAs on the prognosis of patients with hepatocellular carcinoma and provides a foundation for novel HCC therapies, especially immunotherapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-024-13276-5.Keywords: Hepatocellular carcinoma, Pyroptosis, miR-6844, Immune infiltration Introduction Primary liver cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, angiosarcoma, and pediatric hepatoblastoma, represent a significant global health burden [1]. Among these, HCC is the most prevalent, ranking as the sixth most common cancer and the third leading cause of cancer-related deaths worldwide. Its incidence is expected to continue rising in the coming years [2]. A major risk factor for HCC is chronic hepatitis B virus (HBV) infection, which is responsible for approximately 50% of HCC cases worldwide [3]. Chronic HBV infection leads to liver cirrhosis, creating a conducive environment for carcinogenesis over time. Additionally, while advances in antiviral therapy have significantly reduced the risk of hepatitis C virus (HCV) infection progressing to HCC, patients who have achieved viral clearance but have a confirmed diagnosis of cirrhosis remain at a heightened risk of developing HCC [4]. This persistent risk highlights the complexity of managing HCC, even in the context of effective antiviral treatment. Current treatment options for HCC, including surgical resection, ablation, liver transplantation, transarterial chemoembolization, and tyrosine kinase inhibitors (such as sorafenib), have demonstrated survival benefits for patients [5]. However, a high percentage of patients with surgical resection or ablation experience tumor recurrence at 5 years [6]. Liver transplantation, while potentially curative, is constrained by the limited availability of suitable donors [7]. Moreover, resistance to sorafenib develops in approximately 30% of patients who initially respond to the treatment within six months [8]. These challenges underscore the urgent need for the development of novel therapeutic strategies to improve patient outcomes. Pyroptosis, a form of programmed cell death characterized by a highly inflammatory response, has emerged as a critical process in cellular defense against infections and maintenance of tissue homeostasis [9]. Pyroptosis is initiated by activation of inflammasome, a multiprotein complex composed of pattern recognition receptor and inflammatory caspases [10]. Activation of classical pathway inflammasomes leads to cleavage and activation of caspase-1, which subsequently cleaves gasdermin D [11]. Cleaved gasdermin D creates pores in cell membranes, leading to cellular swelling, membrane rupture, and release of pro-inflammatory cellular contents [12]. Non-classical pathway inflammasome caspase-4/5/11 can bind to intracellular lipopolysaccharide (LPS) to trigger self-cleavage and activation [13]. This inflammatory response helps the immune system defend itself against pathogens. Recent studies have revealed the intricate interactions between pyroptosis and various pathological conditions, including cancer. Miltirone triggers hepatocellular carcinoma cell death by inducing GSDME-dependent pyroptosis [14]. Inhibition of CHMP3 and NEK7 suppressed hepatocellular carcinoma proliferation through caspase-1 pathway [15, 16]. Understanding the molecular mechanisms underlying pyroptosis and hepatocellular carcinoma development holds the promise of identifying new therapeutic targets and refining strategies for treating this challenging malignancy. It also suggests that miRNAs may play a role in the regulation of pyroptosis. MiR-122a and miR-141 are implicated in modulating the pyroptotic signaling pathway by targeting NLRP3, potentially influencing the activation or inhibition of pyroptosis [17, 18]. Extracellular vesicles released by human umbilical cord mesenchymal stem cells inhibit hypoxia/reoxygenation-induced pyroptosis in cardiomyocytes through the miRNA-100-5p/FOXO3/NLRP3 pathway [19]. Overexpression of METTL3 attenuates high-glucose-induced pyroptosis in retinal pigment epithelial cells by modulating the miR-25-3p/PTEN/Akt signaling cascade [20]. The long non-coding RNA KLF3-AS1 in extracellular vesicles derived from bone marrow mesenchymal stem cells improves pyroptosis in cardiomyocytes through the miR-138-5p/Sirt1 axis [21]. Exosome-mediated miR-93-TXNIP-NLRP3 signaling pathway induces functional differences between M1 and M2 macrophages in sepsis-induced acute kidney injury [22]. These studies highlight the crucial role of miRNA pathways in activating or inhibiting pyroptosis, providing new insights into understanding and regulating the pyroptotic process. Recent studies have revealed the intricate interplay between pyroptosis and HCC development, illuminating potential therapeutic targets for this challenging malignancy. miRNAs have emerged as key actors in the regulation of pyroptosis, providing promising avenues for therapeutic intervention. In this study, we established a prognostic model based on pyroptosis-associated differentially expressed miRNAs (DEmiRNAs) and performed an analysis of immune cell infiltration and functional correlation of co-expressed differential genes. As we continue to unravel the complexity of pyroptosis and miRNA pathways, the prospect of personalized and effective therapies for HCC seems highly promising. Materials and methods Data download and pre-processing Data were obtained from the The Cancer Genome Atlas Database (TCGA) database download on August 7, 2023 containing miRNA expression data and clinical information for 375 hepatocellular carcinoma patients and 50 healthy control samples. Gene expression data were normalized and preprocessed using the ‘limma’ package. An initial search was performed in Genecards (https://www.genecards.org/) using the keyword ‘pyroptosis’ and the top 25 genes were screened for specificity based on a relevance score threshold. Datasets for miRNA analysis in hepatocellular carcinoma miRNA expression datasets relevant to hepatocellular carcinoma (HCC) were obtained from The Cancer Genome Atlas (TCGA, Accession Number: TCGA-LIHC). Preprocessing of raw data involved quality control using FastQC, adapter trimming with Trimmomatic, alignment to the human reference genome (GRCh38) using HISAT2, and normalization of miRNA expression levels using the Trimmed Mean of M-values (TMM) method. Identification of miRNAs targeting pyroptosis-related genes A list of 25 selected pyroptosis-associated genes was entered into TargetScan, which predicts miRNA-mRNA interactions based on the presence or absence of conserved binding sites within the 3’ untranslated region (UTR) of the target gene. We used a predictive confidence score threshold to select miRNAs most likely to target these genes to ensure specificity and reduce false positive results. We further refined the initial list of 4,024 miRNAs by considering only those miRNAs with contextual scores below a predetermined threshold, which suggests stronger predicted binding affinities. Differential expression analysis of microRNAs The analysis of differentially expressed miRNAs (DEmiRNA) was performed using ‘DESeq2’ after comparing HCC patients with healthy samples to identify miRNAs associated with pyroptosis genes. Plotting of volcanoes was performed with the R package ‘ggplot2’, and heatmaps were plotted with ‘pheatmap’. Construction of a prognostic risk model for pyroptosis-related miRNAs The candidate DEmiRNAs were screened by univariate and multivariate regression analyses. Least Absolute Shrinkage and Selection Operator Regression (LASSO) regression analyses were conducted to identify the optimal number of candidate genes by the ‘glmnet’ package. Cross validation was used to select the optimal lambda (penalty coefficient) and the ‘cv.glmnet’ function in the ‘glmnet’ package was used for this purpose. Risk scores were calculated for each individual in the study using this formula: risk score = ∑Coef miRNA × log2(miRNA expression + 1). The study subjects were categorized into low risk (LR) and high risk (HR) groups based on the median risk score. Validation of the independent predictive model The risk scores were subjected to principal component analysis (PCA) using the ‘stats’ and ‘ggplot2’ packages to demonstrate the sample distribution and verify the accuracy of sample grouping. Kaplan-Meier survival analysis was used to compare the overall survival of HCC patients in the LR and HR groups. ROC curve analysis was performed using the ‘pROC’ package, and AUC values were calculated to assess the predictive ability of the model. Calibration curves were analyzed for 1-, 3-, and 5-year overall survival using the ‘rms’ package to estimate model performance. Univariate and multivariate Cox regression analyses combining risk scores and clinical parameters (e.g., tumor stage, gender, and age) were performed with the ‘survival’ package. Differentially expressed gene and pathway enrichment analysis Venn diagram analysis was performed using the ‘VennDiagram’ package to identify differentially expressed genes (CoDEGs) between the Low Immunity Score (LIS) and High Immunity Score (HIS) cohorts and the LR and HR cohorts. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and Gene Ontology (GO) analysis using ‘clusterProfiler’ and ‘org.Hs.eg.db’ packages to reveal key pathways and biological processes of enrichment. Immunocyte infiltration and immune function analysis Single-sample gene set enrichment analysis (ssGSEA) was conducted to evaluate 28 immune cell infiltrates and 13 immune functions in HCC utilizing GSVA and the ‘ConsensusClusterPlus’ package. Spearman correlation analysis was used to investigate the correlation between immune cells and functions, with correlation coefficients closer to 1 represents a stronger correlation. CoDEGs were analyzed in association with 16 immune cell subtypes and 13 immune functions. Cell culture HepG2 (Procell Life Science & Technology Co., Ltd.) cells were cultured in MEM (Hyclone; Cytiva); Huh‑7 (Nanjing KeyGen Biotech Co., Ltd.) cells were cultured in DMEM (Hyclone; Cytiva). Both of the cell lines were cultured in a 37 °C humidified incubator (Thermo, Waltham, MA, USA) with a 5% CO2 environment. RNA isolation and quantitative RT-PCR Cellular RNA was obtained by Trizol (9109, Takara, Shiga, Japan) extraction. Extracted RNA was reverse transcribed with the StarScript III miRNA RT Kit (by stem-loop) (A237, GenStar, Beijing, China) to obtain cDNA. qRT-PCR is applied with the ABI Prism 7700 Sequence Detection System, steps as follows: 95° C for 5 min, 40 cycles of 95° C for 30 s, 60° C for 45 s, and 72° C for 90 s and 72° C for 10 min. Relative expression of miR-6844 was analysed using the 2-ΔΔCT method. ChamQ Universal SYBR qPCR Master Mix (Q711-02, Vazyme, China) was the reagent used to perform qPCR. The primer sequences involved in this study are as follows: miR-6844: F 5′-AGCGCACAGACACTAAC-3′, R 5′-AATGTGGCACAGAACA-3′. GAPDH: F 5′-TGCACCACCAACTGCTTAGC-3′, R 5′-GGCATGGACTGTGGTCATGAG-3′ siRNA transfection Cell transfection was carried out using Lipofectamine 2000 Reagent (11668-019, Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. The transfection efficiency was verified by qPCR and Western blot 24 h after transfection. The sequence of siRNA: 5′-UUCUUUGUUUUUAAUUCACAG-3′ (Catalog: 4464084, Ambion, Life technologies Corp.) The sequence of miR-6844 siRNA-NC: 5′-UGCCUGGCACAGAUCC-3′ (Catalog: 4464076; Ambion, Life technologies Corp.) MTS assay Hepatocellular carcinoma cells were inoculated into six-well culture plates. For about 24–48 h, the cells were digested, resuspended and counted after observing good cell status. Three replicate wells were set up for each group every day, and 5000 cells per well were inoculated evenly in 96-well plates for 4 consecutive days of measurement. In addition, one column of wells in the 96-well plate was left to add only complete medium as a control, and sterile saline was added to the remaining empty wells to prevent over-drying in the plate. Before each measurement, 20 µL (5 mg/mL) of MTS was added to the measurement wells, and the absorbance (490 nm) was measured after 2 h of incubation. MTS kit is purchased from abcam (ab197010, UK) and measured using Varioskan LUX (Thermofisher, US). Transwell migration and matrigel invasion assays The main steps of the Transwell migration and Matrigel (Corning, Corning, NY, NY, USA) invasion assays were as follows: first, the Matrigel was diluted with serum-free medium (1:9) and then dripped into the upper part of the chambers (50 µL a chambers), gently shaken well and then placed into a constant temperature incubator at 37 °C. After 4 h, 5 × 104 (100 µL) cells and 600 µL serum-free medium were added to the upper layer, and complete medium was added to the lower layer. 24 h (migration assay) /36 h (invasion assay) later, the chambers were taken and fixed with methanol, stained with hematoxylin-eosin, dried, and photographed under a microscope for observation and counting. Statistical analysis Statistical analyses were performed using IBM SPSS Statistics 26 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). All experiments were conducted at least three times to ensure reproducibility. Error bars in the statistical graphs represent standard error of the mean (S.E.M.) as indicated in the figure legends. The following statistical methods were applied: Student’s t-test: Used for comparing two independent groups. Paired t-test: Applied for comparing paired or matched samples. One-way analysis of variance (ANOVA): Used for comparing more than two groups, followed by post-hoc tests (Tukey’s or Bonferroni) where appropriate. Log-rank test: Employed for comparing survival curves between groups. Cox proportional hazards regression model: Used for univariate and multivariate survival analysis. LASSO regression: Used for selecting the most relevant miRNAs associated with overall survival. Significance levels are indicated by asterisks in the figures as follows: *p < 0.05, **p < 0.01, ***p < 0.001. All p-values were two-sided, and a p-value of less than 0.05 was considered statistically significant. Data availability The original contribution proposed in this study is included in the article and further inquiries can be directed to the corresponding author. Results Exploring DEmiRNAs targeting pyroptosis-related genes in hepatocellular carcinoma In this study, we examined in depth the prognostic modeling of pyroptosis-associated gene-miRNAs in hepatocellular carcinoma (HCC) through the detailed workflow shown in Fig. 1. Workflow of this study Firstly, 25 genes associated with pyroptosis were screened in GeneCards with an association level of > 5 (see Supplementary Table S1 for details). Next, we identified 4024 miRNAs targeting these pyroptosis-related genes in TargetScan (see Supplementary Table S2 for details). After comparing 375 HCC patients and 50 healthy samples, we identified 91 pyroptosis-related miRNAs (pyroptosis-miRNAs) (Fig. 2A). The results showed 77 up-regulated and 14 down-regulated DEmiRNAs (see Supplementary Table S3 for details), and the differential expression patterns of the top 20 DEmiRNAs are shown as heatmaps in Fig. 2B. This comprehensive study provided insights into the regulatory network of pyroptosis-related genes in HCC and provided useful insights for further exploration of potential therapeutic targets. Differential expression of pyroptosis-related miRNAs in HCC and normal tissues. (A) Volcano plot showing differentially expressed miRNAs (DEmiRNAs) in normal (N) and tumor (T) tissues. Red dots represent up-regulated miRNAs, and green dots represent down-regulated miRNAs. (B) Heatmap displaying the top 20 differentially expressed miRNAs between HCC and normal tissues Prognostic assessment of risk models based on ten DEmiRNAs In this study, we screened ten DEmiRNAs by univariate and multivariate regression analysis (Fig. 3A, B): hsa-miR-767, hsa-miR-1266, hsa-miR-621, has-miR-421, hsa-miR-760, hsamiR-137, hsa-miR-6844, hsa-miR-578, hsa-miR-3911, and hsa-miR-346. We further confirmed these ten as the optimal number of candidate genes by LASSO regression analysis (Fig. 3C, D). Construction of risk scores for prognostic models based on pyroptosis-related miRNAs. (A) Univariate Cox regression analysis used to identify 10 prognosis-related miRNAs. (B) Forest plot summarizing the results of multivariate Cox regression analysis. (C-D) Least absolute shrinkage and selection operator (LASSO) regression analysis for selecting the optimal miRNAs associated with overall survival Subsequently, we developed a prognostic risk regression model. All subjects were categorized into low-risk (LR) and high-risk (HR) groups based on the median risk score after calculating their risk scores. The results of principal component analysis (PCA) confirmed the accuracy of the grouping, which clearly demonstrated a marked separation between the HCC cases in the LR and HR groups (Fig. 4A, B). The validity of the sample grouping was further demonstrated in Fig. 4C, which shows that the mortality rate in the HR group was significantly higher than that in the LR group. Kaplan-Meier survival analysis showed that the overall survival rate of HCC patients in the HR group was significantly lower than that in the LR group (Fig. 4D). The predictive ability of the risk model was assessed by receiver operating characteristic (ROC) analysis, which revealed that the areas under the curve (AUCs) for overall survival (OS) were 0.639, 0.696, and 0.749 at 1, 3, and 5 years, respectively (Fig. 4E). These AUC values collectively suggest that the diagnostic strength of the miRNA panel improves over time, reaching a moderate level for longer-term predictions (5-year). This result suggests that the risk model has moderate diagnostic strength (Fig. 4F). Validation of the pyroptosis-related miRNA prognostic model. (A) PCA plot of HCC patients grouped by risk scores. (B) Distribution of risk scores for the patient cohort. (C) Survival status distribution of patients. (D) Kaplan-Meier survival curves comparing low-risk and high-risk groups. (E) ROC curves for predicting 1-, 3-, and 5-year overall survival. ROC analysis was used to calculate AUC values. (F) Calibration curves for 1-, 3-, and 5-year overall survival. (Number of High-Risk Samples: 183. Number of Low-Risk Samples: 183) Comprehensive risk score and clinical parameters to predict prognosis In this study, the independent predictive potential of the constructed risk model in HCC was elucidated using univariate and multivariate Cox regression analyze, combining risk scores with clinical parameters. As shown in Fig. 5A-B, the study identified risk score and tumor stage as independent prognostic factors. The results of univariate Cox regression analysis (P < 0.001) showed a significant association between risk score [hazard ratio (HR) = 2.3348, 95% confidence interval (CI) = 1.5780–2.0514] and tumor stage [HR = 1.6666, 95% CI = 1.3540–2.0514]. Multivariate Cox regression analysis (P < 0.001) further validated the independent predictive significance of risk score [HR = 2.1174, 95% CI = 1.4078–3.1847] and tumor stage [HR = 1.6522, 95% CI = 1.3345–2.0455]. Additionally, the nomogram combines risk scores with critical clinical variables such as stage, gender, and age to provide a comprehensive tool for predicting the prognosis of patients with HCC (Fig. 5C). Survival analysis of the prognostic value of miRNA candidate genes in hepatocellular carcinoma patients showed that patients with high expression of hsa-miR-137, hsa-miR-760 and hsa-miR-6844 had significantly lower survival than those with low expression (Fig. 5D-F). Development of predictive nomograms for HCC prognosis. (A) Univariate Cox regression analysis of risk scores and clinical characteristics in the HCC cohort. (B) Multivariate Cox regression analysis. (C) Nomograms for predicting 1-, 3-, and 5-year survival in HCC patients. (D-F) Kaplan-Meier survival curves showing the prognostic value of hsa-miR-137, hsa-miR-760, and hsa-miR-6844 Differential expression and pathway enrichment analysis The Venn diagram (Fig. 6A) demonstrated the intersection of 1048 differentially expressed genes between the LR and HR cohorts with low immunity score (LIS) and high immunity score (HIS). These genes, considered as co-differentially expressed genes (CoDEGs) were the focus of our further study. The critical pathways of enrichment were revealed by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis (Fig. 6B), with the most significant being neuroactive ligand-receptor interactions. Gene Ontology (GO) analyses revealed that the organization of the extracellular matrix, extracellular structures, and external encapsulating structure in the biological process (BP) of CoDEGs were significantly enriched in our data, and these findings underscore the critical role of the extracellular environment in disease development. The cellular components (CC) include immunoglobulin complexes and presynaptic membranes. Molecular functions (MF) include receptor ligands and passive transmembrane transporter activity (Fig. 6C-D). These changes in biological function provide us with valuable insights into the molecular foundation of HCC. Functional enrichment analysis of coDEGs. (A) Venn diagram identifying 2,378 coDEGs in HCC. (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis for coDEG enrichment. (C) Bar graph showing KEGG pathway enrichment analysis. (D) Dot plot representing Gene Ontology (GO) enrichment analysis for coDEGs Differential immune infiltration and function and gene expression correlations analysis The single sample Gene Set Enrichment Analysis (ssGSEA) investigated 28 immune cell infiltrates (ICI) and 13 immune functions in HCC. The heatmap (Fig. 7A) specifically highlighted T helper cells, human leukocyte antigen (HLA), major histocompatibility complex (MHC) class I, para-inflammation and type I interferon (IFN) response as important elements in the tumor immune microenvironment. Spearman’s correlation analysis results indicated significant correlations between Th1 cells and tumor-infiltrating lymphocytes (TIL) (r = 0.87) and between CD8 + cells and TIL (r = 0.86) with respect to ICI (Fig. 7B). For immune function, the correlations were strongest between immune checkpoints and T cell co-inhibition (r = 0.93) and between immune checkpoints and T cell co-stimulation (r = 0.92) (Fig. 7C). On the basis of ssGSEA score in a cohort of HCC patients, it was found that aDCs, iDCs, macrophages and Treg were increased in the high-risk cohort compared to the low-risk cohort, whereas B-cells, CD8 + T-cells, mast-cells, neutrophils and NK-cells were decreased (Fig. 7D). Among immune functions, MHC class I responses were more prominent in the high-risk cohort, with reduced cytolytic activity, inflammation-promoting, and type I/II IFN responses (Fig. 7E). We further explored the correlations between coDEGs and 16 immune cell subtypes or and 13 immune functions. Correlation analysis of ssGSEA scores with immune cells and immune function. (A) Heatmap showing single-sample Gene Set Enrichment Analysis (ssGSEA) scores for immune cell (imc) infiltration and immune function (imf). (B-C) Correlation analysis between immune cell infiltration and immune function. (D-E) Box plots comparing ssGSEA scores for different immune cells and functions between high-risk and low-risk populations. *p < 0.05, **p < 0.01, ***p < 0.001; ns: not significant Fig. 8 displayed the correlation of coDEGs expression with ICI levels and immune functions, in which musculin (MSC) and C-Type Lectin Domain Family 5 Member A (CLEC5A) were more significant. Correlation of coDEG expression with immune cell infiltration and function Effects of miR-6844 on proliferation, migration and invasion of hepatocellular carcinoma cells In order to explore the effect of miR-6844 on the malignant degree of hepatocellular carcinoma, we designed and carried out cytological experiments. We transfected Huh-7 and HepG2 cell lines with siRNA and verified the knockdown efficiency by qPCR (Fig. 9A). We studied the effect of miR-6844 on the proliferation of hepatocellular carcinoma by MTS assay. The results showed that the proliferation of Huh-7 and HepG2 cells were inhibited after knockdown miR-6844, especially the proliferation of Huh-7 cells was obviously inhibited at 48 h (Fig. 9B). In addition, we performed a Transwell migration assay and a scratch assay to investigate the changes in the migratory ability of hepatocellular carcinoma cells. The migration rate of hepatocellular carcinoma cells was significantly reduced after knockdown of miR-6844 compared with the control groups (Fig. 9C, D). Finally, in the Transwell invasion assay, we found that miR-6844 also played a role in the invasive ability of hepatocellular carcinoma cells (Fig. 9E). With these experimental results we analyzed that miR-6844 promotes the malignant ability of hepatocellular carcinoma cells. Effects of miR-6844 on the biological functions of hepatocellular carcinoma cell lines. (A) Relative expression levels of miR-6844 post-transfection measured by Real-time PCR in different groups. (B) Line graph showing MTS assay results for HepG2 and Huh-7 cell viability. (C) Results of the scratch wound healing assay, with the right panel showing a statistical bar graph. (D) Transwell migration assay results with a corresponding statistical bar graph. (E) Transwell invasion assay results with a corresponding statistical bar graph. *p < 0.05, **p < 0.01, ***p < 0.001 Discussion The latest advances in cancer research have highlighted the critical role of pyroptosis in the fight against various cancer types. Studies have shown that down-regulating miR-155-5p enhanced the anti-tumor effects of cetuximab in triple-negative breast cancer (TNBC) by inducing apoptosis and pyroptosis [23], which provides new therapeutic perspectives for this challenging cancer subtype. Similarly, targeting the ZNF-148/miR-335/SOD2 signaling cascade, which could trigger oxidative stress-mediated pyroptosis and impede breast cancer progression [24], has emerged as a promising strategy. In the field of lung cancer, especially non-small cell lung cancer (NSCLC), it has been found that the use of sodium new houttuyfonate activates pyroptosis through the TCONS-14,036/miR-1228-5p/PRKCDBP pathway [25]. Knockdown of miR-556-5p in NSCLC has been shown to enhance cisplatin sensitivity by activating NLRP3-mediated pyroptosis cells [26]. Additionally, down-regulation of LncRNA-XIST was observed in NSCLC to activate the miR-335/SOD2/ROS signaling pathway, which also resulted in pyroptosis [27]. Moreover, the study of the pyroptosis-related LINC01133 in pancreatic adenocarcinoma revealed its role in inhibiting cancer progression through the miR-30b-5p/SIRT1 axis [28]. Knockdown of FLOT1 in acute myeloid leukemia (AML) cells resulted in apoptosis and pyroptosis followed by growth inhibition [29], further emphasizing the promise of pyroptosis as a cancer therapeutic strategy. In this study, we have thoroughly investigated the role of DEmiRNAs related to pyroptosis genes in hepatocellular carcinoma. A prognostic risk model could effectively differentiate between high- and low-risk HCC patient groups, from which three DEmiRNAs with statistically significant overall survival time were screened. Recently, miR-137 has been shown to exert a significant role in the progression of HCC. miR-137 not only suppressed the proliferation and metastasis of HCC cells [30], but also regulated the hepatic microenvironment through its target of AFM [31]. The up-regulation of miR-137 was observed to inhibit the PTEN/Akt signaling pathway by interacting with DNMT3a, thereby restraining the growth and progression of tumors [32]. This up-regulation also reduced phenotypes of cancer-initiating cell phenotypes through the degradation of ANT2, which is essential for overcoming sorafenib resistance [33]. These findings characterize miR-137 as a promising biomarker and a potential target for therapeutic intervention in HCC [34]. In addition, it has been found that miR-760 reduces proliferation, migration and invasion of HCC cells by targeting HMGA2 [35] and NACC-1 [36], and the latter enhances sensitivity to the chemotherapeutic agent doxorubicin. Recent studies have further highlighted the significance of miR-6844 in cancer biology. For example, miR-6844 has been implicated in a novel prognostic miRNA-mRNA network associated with hepatocellular carcinoma progression, revealing its potential as a biomarker and therapeutic target [37]. Additionally, downregulation of miR-6844 reduced the stemness/self-renewal capacity of breast cancer stem cell-like cells through the CD44-JAK2-STAT3 axis, and also diminished migrating and invading cells [38]. There are currently no findings regarding the impact of miR-6844 on hepatocellular carcinoma (HCC) progression. However, the expression patterns of miR-6844 suggest that it may regulate other aspects of tumor biology, such as growth and resistance to therapies. Furthermore, a study that identified cancer stemness-related miRNAs through integrated bioinformatics analysis and in vitro validation supports the idea that miR-6844 may be linked to cancer stemness in other cancer types [39]. This potential connection could provide insights into the role of miR-6844 in promoting tumor aggressiveness and therapy resistance. In this study, we elucidated the critical role of miR-6844 in regulating the malignant behavior of hepatocellular carcinoma cells. Our experiments demonstrated that knockdown of miR-6844 significantly inhibited the proliferation, migration, and invasion of Huh 7 and HepG2 cell lines. These findings suggest that miR-6844 may act as an oncogenic miRNA in HCC, promoting tumor progression through multiple pathways. Given its substantial impact on tumor cell behavior, miR-6844 represents a promising target for therapeutic intervention in HCC, and future studies should explore this potential in more depth. The TIRAP gene was identified as a potential target of miR-6844 through TargetScan analysis, with a Cumulative Weighted Context + + Score of -1, indicating a significant likelihood of interaction. TIRAP, an adaptor protein in the Toll-like receptor (TLR) signaling pathway, is crucial for activating the NLRP3 inflammasome and initiating pyroptosis [40]. Recent studies have highlighted TIRAP’s role in promoting inflammasome activation and contributing to inflammatory responses in various cancers [41, 42], suggesting that miR-6844 may modulate pyroptotic cell death by downregulating TIRAP. This regulation could affect the tumor immune microenvironment and response to therapy. A complete list of miR-6844 target genes is included as an attachment in the Supplementary Material. Furthermore, we found that these miRNAs were strongly associated with immune infiltration and immune function, especially in the high-risk patient population, observing an increase in specific immune cell types (e.g., aDCs, iDCs, macrophages, and Treg). In the evolving study of hepatocellular carcinoma, recent studies have highlighted important interactions between miRNAs, long non-coding RNAs (lncRNAs) and the immune landscape, revealing novel mechanisms of immune evasion and potential therapeutic targets. Complementarily, the lncRNA FENDRR acts as a sponge for miR-423-5p and regulated Treg-mediated immune escape from HCC cells [43]. The LINC00638/miR-4732-3p/ULBP1 axis associated with tumor mutational load facilitated immune escape through PD-L1, highlighting the intricate molecular network at work [44]. The complexity of this interaction is further illustrated by the fact that miR-146a, which is directly regulated by STAT3, is thought to be associated with antitumor immunosuppression in HCC [45]. Additionally, miR-29c suppressed the malignant phenotype of HCC cells by mediating TPX2 associated with immune infiltration [46]. lncRNA MIAT targeting the miR-411-5p/STAT3/PD-L1 axis further elucidated the mechanisms mediating the immune response in HCC [47]. KCNQ1OT1 knockdown inhibited sorafenib resistance and PD-L1-mediated immune escape by sponging miR-506 in sorafenib-resistant HCC cells [48]. Similarly, CircSOD2 promoted tumor progression, immune escape, and resistance to anti-PD-1 therapy in hepatocellular carcinoma by targeting the miR-497-5p/ANXA11 axis [49]. miR-570 was identified as an inhibitor of HCC proliferation, angiogenesis, and immune escape [50]. miR-429 inhibited the formation of an immunosuppressive microenvironment by targeting PD-L1, which counteracted immune escape in HCC [51]. Furthermore, hsa-miR-9-5p-mediated downregulation of TSPAN9 was positively associated with poor HCC prognosis and increased tumor immune infiltration [52]. Innovative co-delivery of Ce6 and miR-195 using nanobubbles was explored to synergize acoustic kinetic and checkpoint blockade combination therapies to elicit powerful immune responses in HCC [53]. Collectively, these studies have elucidated the multifaceted role of miRNAs in regulating the immune landscape of HCC, providing promising avenues for therapeutic interventions aimed at enhancing the immune response and combating the immune evasion mechanisms of this complex malignancy. The differential expression and pathway enrichment analysis of miRNAs associated with pyroptosis revealed significant involvement in several key pathways, including neuroactive ligand-receptor interactions, calcium signaling, IL-17 signaling, and extracellular matrix organization. These pathways are known to play critical roles in regulating both immune responses and pyroptotic cell death. Enrichment of calcium signaling pathway suggests that miRNAs may influence NLRP3 inflammatory vesicle activation and cell pyroptosis by regulating intracellular calcium ion flow. It was shown that calcium-sensitive receptors regulate NLRP3 inflammatory vesicles through the Ca2 + and cAMP pathways, further highlighting the important role of calcium signaling in pyroptosis [54]. The extracellular matrix (ECM) organisation pathway was identified as a key pathway, suggesting that miRNAs may play a role in maintaining tissue homeostasis and regulating immune responses by influencing the structural integrity and remodelling of the ECM. This finding is consistent with recent studies that have highlighted the importance of ECM components in regulating cell pyroptosis. For instance, exosome-functionalised ECM hydrogels for injection have been shown to restore metabolic homeostasis and modulate cell pyroptosis in disc degeneration, highlighting the therapeutic potential of targeting ECM-related pathways to reduce inflammatory cell death [55]. In addition, quercetin has been reported to attenuate oxidative stress-mediated chondrocyte pyroptosis and ECM degradation, further emphasising the interplay between ECM components and cell pyroptosis processes in maintaining tissue health [56]. In addition, it was found that MFG-E8 inhibited cell pyroptosis via the Nrf2/TXNIP/NLRP3 axis and prevented ECM degradation of nucleus pulposus cells, thereby alleviating disc degeneration, providing another potential therapeutic strategy to control cell pyroptosis-associated tissue damage by targeting the ECM [57]. Collectively, these findings underscore the dual role of the miRNAs studied in modulating both immune responses and pyroptosis-related pathways. Our study has several limitations that should be acknowledged. Firstly, we relied solely on data from TCGA, which may limit the generalizability of our findings to other populations, and validation using additional datasets is needed. Additionally, the ten DEmiRNAs selected for the prognostic panel were chosen based on their combined effect in a multivariate model, not solely on their differential expression or individual Hazard Ratios, which may vary across different datasets. There are also limitations in the experimental methods; the in vitro results, such as miR-6844 knockdown, may not fully represent the in vivo situation, and our understanding of the biological mechanisms by which miRNAs affect the HCC process remains restricted. Future studies should include in vivo experiments, such as tumorigenesis studies in nude mice and pathway exploration using techniques like western blotting, to confirm these findings. Moreover, translating these findings into clinical practice presents challenges, and further research involving clinical sample collection is needed to enhance their potential applicability. In conclusion, our study not only provides new insights into the role of pyroptosis-associated miRNAs in the progression of HCC, but also provides a basis for the development of novel therapeutic approaches against HCC, especially in the field of immunotherapy. Future studies will aim to overcome the existing limitations with a view to realizing the clinical application of these findings and bringing new hope to patients with HCC. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Acknowledgements The authors sincerely thank all of the members. Abbreviations Hepatocellular carcinoma Hepatitis B virus Hepatitis C virus Differentially expressed miRNAs Least Absolute Shrinkage and Selection Operator Regression Principal component analysis Low Immunity Score High Immunity Score Small interfering RNA The Cancer Genome Atlas Overall survival Gene Oncology Kyoto Encyclopedia of Genes and Genomes Negative control Single-sample gene set enrichment analysis Immune cell infiltrates Human leukocyte antigen Major histocompatibility complex Tumor-infiltrating lymphocyte C-Type Lectin Domain Family 5 Member A Triple-negative breast cancer Non-small cell lung cancer Long non-coding RNA Author contributions Yuting Zheng was responsible for writing the full text, the experimental part was done by Xing Huang and compiled the results. Funding No particular funding was received from any individual or organization for this study. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Data Availability Statement The original contribution proposed in this study is included in the article and further inquiries can be directed to the corresponding author. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.